Skip to content
The Policy VaultThe Policy Vault

SovaldiMedica

genotype 2 or 3 chronic hepatitis C virus, pediatric patients ≥ 3 years and <18 years (new start)

Preferred products

  • Epclusa (brand)

Initial criteria

  • For genotype 2 or 3 chronic HCV pediatric patients (≥3 to <18 years) – new start: Sovaldi is not approved; offer to review for Epclusa (brand only) using the standard Hepatitis C – Epclusa PA Policy criteria.
  • For patient continuing therapy with Sovaldi: refer to the standard Hepatitis C – Sovaldi PA Policy criteria.

Approval duration

as specified in the respective standard Hepatitis C PA Policy